Overview:
The incidence of radiation toxicity is on a rise with increase in treatment and diagnosis of various diseases using radiation therapy and nuclear medicine, thus driving the overall market growth. Cancer treatment predominantly utilizes radiation therapy to treat tumours and cancerous cells. Growing prevalence of cancer thus increases the rate of radiation therapy indicating growing risk of radiation toxicity. The American Cancer Society projected 1,735,350 new cancer cases to occur in US in the year 2018 and further estimated 609,640 deaths to occur in the similar year. Based on various research studies, around 60% patients undergo radiation therapy of which 5-10% experience radiation toxicity. However, the high cost of radiation therapy would lead to lesser patients opting for it particularly in low and middle-income regions. This factor could reduce the rate of radiation toxicities thus restraining the market growth.
The treatment options for radiation toxicity comprise bone marrow transplant, blood/ platelet transfusion (used to treat anaemia conditions), and antibiotics (prescribed to diminish the threats of various infections). Aeolus pharmaceuticals is currently developing (Phase I) a molecule named AEOL-10150 for the treatment of acute radiation syndrome.
Radiation toxicity can occur due to either intentional exposure to radiations or accidental exposure such as nuclear power plant accidents. Providing first aid to radiation victims may also increase the risk of exposure of radiation to the rescue personnel. The rising number of respective patients has attracted many pharmaceutical industries to invest in this market and carry out various research activities in development of suitable therapies.
North America predominates the global radiation toxicity treatment market, which is followed by Europe. The dominance is attributed to the growing awareness on available treatment options. Asia Pacific is also a potential market owing to its developing healthcare infrastructure, rising awareness on healthcare and growing cancer prevalence.
The Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market is segmented as follows:
- By Treatment
- Antibiotics
- Blood products
- Colony stimulating factors
- Bone marrow transplant
- Stem cell transplant
- Blood/platelet transfusions
- Pipeline products
- Tempol ( Phase II)
- AEOL-10150 (Phase I)
- By Geography
- North America
- Europe
- U.K
- Germany
- Rest of Europe
- Asia Pacific
- Japan
- China
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- Rest of Middle East and Africa
The key industrial players enjoying supremacy in this market are Aeolus Pharmaceuticals, Cantex Pharmaceuticals, Inc., Cleveland BioLabs, Inc., Gamida Cell Ltd., Nanotherapeutics, Inc., NeoStem, Inc., Onconova Therapeutics, Inc., Osiris Therapeutics, Inc. and Tonix Pharmaceuticals Holding Corp.
This report offers:
- An overview of global radiation toxicity (radiation sickness, acute radiation syndrome) treatment market
- Market outlook and in depth analysis for the period from 2016 to 2026, with 2016 as the historical year and 2017 as the base year
- Annual growth rates for the period from 2018 to 2026 pertaining to the entire market and each segment have also been included in this report
- Qualitative information with respect to market drivers, opportunities and restraints
- A complete understanding on the competitive landscape and profiles of key market players
